US college endowments overseeing $500 million or more posted median returns of 11.5% for the year through June, the best performance since 2021. All endowments including smaller funds gained a median ...
Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback